MX2023005459A - Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4- carboxilico y un proceso para su preparacion. - Google Patents

Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4- carboxilico y un proceso para su preparacion.

Info

Publication number
MX2023005459A
MX2023005459A MX2023005459A MX2023005459A MX2023005459A MX 2023005459 A MX2023005459 A MX 2023005459A MX 2023005459 A MX2023005459 A MX 2023005459A MX 2023005459 A MX2023005459 A MX 2023005459A MX 2023005459 A MX2023005459 A MX 2023005459A
Authority
MX
Mexico
Prior art keywords
oral formulation
indol
pyrazole
cyano
isopropyl
Prior art date
Application number
MX2023005459A
Other languages
English (en)
Inventor
Duck Il Yun
Seok Cheol Yoo
Sun Lee
Junghong Park
Hyun Ji Sun
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MX2023005459A publication Critical patent/MX2023005459A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una formulación oral estable que comprende ácido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4-ca rboxílico o una sal farmacéuticamente aceptable de este como un API. La formulación oral estable según la presente invención tiene la característica de mantener la estabilidad incluso si no comprende un estabilizador como excipiente y no comprende un estabilizador, pero tiene un contenido de API elevado y, por lo tanto, la conveniencia de la administración puede aumentar.
MX2023005459A 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4- carboxilico y un proceso para su preparacion. MX2023005459A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20200166051 2020-12-01
PCT/KR2021/017842 WO2022119269A1 (ko) 2020-12-01 2021-11-30 1-(3-시아노-1-아이소프로필-인돌-5-일)피라졸-4-카르복실산을 포함하는 안정한 경구용 제제

Publications (1)

Publication Number Publication Date
MX2023005459A true MX2023005459A (es) 2023-05-23

Family

ID=81854222

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005459A MX2023005459A (es) 2020-12-01 2021-11-30 Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4- carboxilico y un proceso para su preparacion.

Country Status (14)

Country Link
US (1) US20240000751A1 (es)
EP (1) EP4257123A4 (es)
JP (1) JP2023551712A (es)
KR (1) KR20220077091A (es)
CN (1) CN116528852A (es)
AR (1) AR124178A1 (es)
AU (1) AU2021390901A1 (es)
CA (1) CA3197405A1 (es)
CL (1) CL2023001215A1 (es)
CO (1) CO2023008265A2 (es)
MX (1) MX2023005459A (es)
PE (1) PE20240222A1 (es)
TW (1) TW202408496A (es)
WO (1) WO2022119269A1 (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05001167A (es) * 2002-07-31 2005-05-16 Pharmacia Corp Capsula de gelatina que exhibe reticulacion reducida.
US20060188569A1 (en) * 2005-01-21 2006-08-24 Teva Pharmaceutical Industries Ltd. Stable pharmaceutical formulations of zonisamide and methods for their manufacture
BRPI0810524B8 (pt) * 2007-04-11 2021-05-25 Kissei Pharmaceutical derivado de (aza)indol, inibidor de xantina oxidase e composição farmacêutica compreendendo o dito derivado
TWI423962B (zh) * 2009-10-07 2014-01-21 Lg Life Sciences Ltd 有效作為黃嘌呤氧化酶抑制劑之新穎化合物、其製備方法及含該化合物之醫藥組成物
TWI548630B (zh) * 2011-04-06 2016-09-11 Ｌｇ生命科學有限公司 １－（３－氰基－１－異丙基－吲哚－５－基）吡唑－４－羧酸結晶型及其製造方法
CN116456979A (zh) * 2020-11-04 2023-07-18 株式会社Lg化学 1-(3-氰基-1-异丙基-吲哚-5-基)吡唑-4-甲酸结晶粒子的制备方法以及包含其的药物组合物

Also Published As

Publication number Publication date
PE20240222A1 (es) 2024-02-16
CO2023008265A2 (es) 2023-06-30
AR124178A1 (es) 2023-02-22
AU2021390901A1 (en) 2023-06-08
KR20220077091A (ko) 2022-06-08
AU2021390901A9 (en) 2024-05-23
CA3197405A1 (en) 2022-06-09
JP2023551712A (ja) 2023-12-12
US20240000751A1 (en) 2024-01-04
WO2022119269A1 (ko) 2022-06-09
CL2023001215A1 (es) 2023-12-15
TW202228679A (zh) 2022-08-01
EP4257123A1 (en) 2023-10-11
TW202408496A (zh) 2024-03-01
EP4257123A4 (en) 2024-05-08
CN116528852A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
PH12019502701A1 (en) Atropine pharmaceutical compositions
NZ603900A (en) Subcutaneous anti-her2 antibody formulation
IN2014CN02592A (es)
NZ702808A (en) Methods and compositions for cns delivery of iduronate-2-sulfatase
MX2019011491A (es) Formulaciones de niraparib.
MX2020007552A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
TNSN06293A1 (en) Ophthalmic solution comprising sodium carboxymethylcellulose and hydroxypropylmethylcellulose
MX2021014029A (es) Formulaciones, fabricación y usos de imatinib.
MX2022009844A (es) Composiciones y usos del peptido similar al glucagon-1 (glp-1).
MX2020005942A (es) Delgada pelicula oral con alta carga de agente activo.
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
JP2014237607A (ja) ペメトレキセドを含む注射用組成物
PH12019501873A1 (en) Pharmaceutical composition
PH12016501877A1 (en) Lypophilized factor ix formulations
ZA202309527B (en) Ionizable lipids and compositions for nucleic acid delivery
MX2023005459A (es) Formulacion compuesta para administracion oral que comprende acido 1-(3-ciano-1-isopropil-indol-5-il)pirazol-4- carboxilico y un proceso para su preparacion.
PE20240139A1 (es) Metodo para la preparacion de la composicion cristalina y farmaceutica acido 1-(3-ciano-1-isopropil-indol-5-yl)pirazol-4-carboxilico que lo comprende
EA033306B1 (ru) Стабилизированный раствор на основе активных веществ, способ получения стабилизированного раствора активных веществ, фармацевтическая композиция на основе стабилизированного раствора активных веществ (два варианта)
MY191261A (en) Novel preparation containing benzimidazole derivative
MX2022000968A (es) Composicion farmaceutica estable que comprende esomeprazol y bicarbonato de sodio.
NO20083213L (no) Farmasoytisk sammensetning inneholdende montelukast
WO2021216450A8 (en) Opioid antagonist formulations
NO20080066L (no) Farmasoytiske preparater av mikronisert (4-klorfenyl) [4-(4-pyridylmetyl)ftalazin-1-yl] og salter derav, med umiddelbar frigivelse og hoyt legemiddelinnhold